WAYNE, Pa., March 13, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX) (NYSE: TFX), a leading global provider of medical technologies, today announced new research from controlled and real-world ...
Men with obstructive median lobes treated with the UroLift® System experience symptom improvement sooner and are satisfied more quickly compared to those treated with TURP, and have fewer post-op ...
WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...
WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (TFX), a global leader in medical technologies, today announced the presentation of new research findings from the 2024 American ...
DUBLIN, Dec. 9, 2025 /PRNewswire/ -- ProVerum Limited, a medical device company focused on innovative, safe and effective solutions for treating benign prostatic hyperplasia (BPH), today announced it ...
A trial of a permanent prostatic urethral stent for treatment of BPH demonstrated early success. A novel prostatic urethral stent can reduce lower urinary tract symptoms (LUTS) in men with benign ...
In a trial, the newly approval urethral stent provided significant and durable relief of BPH-related LUTS over 12 months. The FDA has approved the ProVee® System for treatment of benign prostatic ...
Rates of surgical retreatment, alongside patient experience factors such as complications and adverse events (AEs), are important considerations when patients and their providers assess BPH therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results